RCT · 2026
Does a second, smaller MDMA dose extend the drug's effects? A crossover trial in 25 adults
- Original title
- Comparison of acute effects of 3,4-methylenedioxymethamphetamine (MDMA) with and without a supplemental booster dose in healthy participants: a double-blind, randomized, placebo-controlled, crossover study.
- Authors
- Humbert-Droz M, Becker AM, Valenta J, et al.
- Journal
- Translational psychiatry, 2026
- Molecules
- MDMA
- Conditions
- Healthy volunteers
- Participants
- 25
- Evidence grade
- Moderate
- Source
- Read the original paper
The question
In trials of MDMA-assisted therapy, a smaller “booster” dose is often given a couple of hours after the first dose. Does that booster actually lengthen the drug’s effects, and does it add risks?
What they did
Twenty-five healthy volunteers were enrolled and 23 (12 male, 11 female) completed all sessions. Each person received three conditions in random order, with neither participants nor researchers knowing which was which: 120 mg of MDMA followed 2 hours later by a 60 mg booster, 120 mg of MDMA followed by a placebo, and placebo followed by placebo. The main measure was how long any subjective drug effects lasted, rated by participants on a simple line scale. Researchers also tracked other subjective effects, side effects, vital signs and blood levels of MDMA, oxytocin and neurophysin I.
What they found
The booster dose made the experience last longer: an average of 5.6 hours (standard deviation 1.8) compared with 4.6 hours (standard deviation 1.2) after a single dose (p = 0.001). The peak intensity of subjective effects and the peak effects on body functions such as heart rate and blood pressure did not differ between the two MDMA conditions. Side effects during the session (0-9 hours) and in the following days (up to 3 days) were more common after both MDMA conditions than after placebo.
The fine print
This was a small study in 25 healthy volunteers, not people receiving treatment for a mental health condition, so it cannot say whether a longer drug experience leads to better therapy outcomes. MDMA produces noticeable effects, which makes true blinding difficult. Follow-up for side effects was limited to about three days. This summary is based on the abstract only.
What it means
The booster dose used in MDMA-assisted therapy trials does what it is meant to do - it stretches out the drug’s effects by roughly an hour on average - without raising peak intensity or peak cardiovascular effects. Whether that extra time actually helps patients is still unknown.
Evidence grade: Moderate. A randomized, double-blind, placebo-controlled crossover trial, but small, in healthy volunteers, and measuring drug effects rather than clinical outcomes.
This summary is based on the study’s published abstract.